Academic literature on the topic 'Euroflow'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Euroflow.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Euroflow"
1
Narita, Kentaro, Takeshi Yoroidaka, Momoko Fujisawa, Hiroyuki Takamatsu, Shinji Nakao, and Kosei Matsue. "Quantification of Residual Bone Marrow Plasma Cells By Eight-Color Flow Cytometry in Patients with Multiple Myeloma: Comparison between the Dura Clone RE PC Panel (Beckman Coulter) and the Euro Flow MM-MRD Panel (Cytognos)." Blood 132, Supplement 1 (November 29, 2018): 3187. http://dx.doi.org/10.1182/blood-2018-99-116108.
Full textAbstract:
Abstract 【Background】The use of novel agents with different mechanisms of action has resulted in high complete response (CR) rates and improved the survival of patients with multiple myeloma (MM). Obtaining minimal residual disease (MRD) negativity following treatment is an important determinant for longer survival in patients with MM. The EuroFlow MM-MRD panel (EuroFlow panel) using the Infinicyt software (Cytognos, Salamanca, Spain) is a two-tube six-color antibody panel. By the addition of two drop-in antibodies (CD138, CD27; vendor of user's choice) into both tubes, an eight-color configuration, which has been validated by the EuroFlow consortium is obtained. The DuraClone RE PC kit (DuraClone panel) is a recently developed one-tube eight-color dry antibody panel using the Kaluza software (Beckman Coulter, Miami, USA) for manual identification of abnormal plasma cells (PCs) to detect MRD in MM. Although both methods are available, a comparison between them has yet to be performed. This study aimed to compare the EuroFlow panel and the DuraClone panel analysis of residual abnormal plasma cells by eight-color flow cytometry. 【Methods】Patients with International Myeloma Working Group defined symptomatic MM treated at Kanazawa University Hospital and Kameda Medical Center in Japan from January 2017 to July 2018 were included. Bone marrow samples were obtained as part of routine clinical practice for evaluating treatment response when appropriate. Bone marrow aspirates (4 mL; first pull of bone marrow aspiration) anti-coagulated with ethylenediamine tetraacetic acid were evenly split (2 mL each) for the EuroFlow panel and the DuraClone panel. PC quantification by the EuroFlow panel was performed at Kanazawa University Hospital and the DuraClone panel was performed at Kameda Medical Center. The monoclonal antibodies used in the EuroFlow and the DuraClone panels are detailed in Table 1. Identification of neoplastic PCs required ≥ 20 cells. Sample processing and measurement of PCs were performed within 48 hours of collection. The correlation of total leukocyte acquisition, total plasma cells and MRD were analyzed for both methods. Qualitative comparison of MRD negativity was also performed. Spearman's correlation coefficient was used for evaluating the correlation of paired data. The Bland-Altman plot was used for detection of fixed bias and proportional bias. 【Results】A total of 79 samples were analyzed. We first assessed the number of total leukocytes using the EuroFlow panel and the DuraClone panel. The median number of total leukocytes acquired with the EuroFlow panel was significantly higher than with the DuraClone panel (median: 8,505,172 cells, interquartile range [IQR]: 6,164,094 - 9,105,097 cells and median: 2,858,026 cells, IQR: 1,466,004 - 4,284,926 cells, respectively; p < 0.01), but the percentage of total plasma cells showed good concordance between both methods (regression coefficient = 0.91, p < 0.01). The median percentage of abnormal plasma cells was 0.0035% (IQR: 0.0005 - 0.05) and 0.0046% (IQR: 0.0005 - 0.05) using the EuroFlow panel and the DuraClone panel, respectively. Figure 1A shows scatter plots comparing the percentage of abnormal cells analyzed using the EuroFlow panel and the DuraClone panel. Both methods showed a high degree of concordance (regression coefficient = 0.90, p < 0.01). Bland-Altman plots also showed good agreement between both methods. There was no statistically significant fixed bias with a mean difference of 10% (95% confidence interval [CI]: -12~14%). In addition, no significant proportional bias was detected between the two methods (regression coefficient: -0.01, p = 0.85; Figure 1B). Qualitative analysis of MRD negativity also showed substantial agreement between the two methods (kappa = 0.7); 11 of 79 (13.9 %) samples showed discrepancy for determination of MRD negativity (< 1 × 10-5). Nine of these samples were MRD negative by the EuroFlow panel, but MRD positive by the DuraClone panel, and two samples were MRD positive by the EuroFlow panel, but MRD negative by the DuraClone panel. However, all discrepancies occurred near the limit of detection of both methods (1.0 × 10-5). 【Conclusion】Our findings indicate that the DuraClone panel has good overall concordance with the EuroFlow panel for the detection of abnormal PCs in MM samples. The one-tube DuraClone panel enables to reduce processing time and test cost compared with the two-tube EuroFlow panel. Disclosures Takamatsu: Celgene: Honoraria, Research Funding; Janssen: Honoraria; Bristol-Myers Squibb: Research Funding; Ono: Research Funding. Nakao:Alexion Pharmaceuticals, Inc.: Consultancy, Honoraria; Kyowa Hakko Kirin Co., Ltd.: Honoraria; Novartis: Honoraria.
2
Okazuka, Kiyoshi, Tadao Ishida, Jun Sakamoto, Nobuhiro Tsukada, and Kenshi Suzuki. "MRD Detection in Myeloma Cells: Comparison between Inexpensive 1-Tube 10 Color Multiparameter Flow Cytometry and Euroflow Multiparameter Flow Cytometry." Blood 134, Supplement_1 (November 13, 2019): 1832. http://dx.doi.org/10.1182/blood-2019-123900.
Full textAbstract:
Background: Achievement of MRD-negative status in MM patients has been demonstrated to be associated with better outcome. EuroFlow MM-MRD has been a global standard for MRD detection by MFC. In Japan, EuroFlow is limited to research use only, because the dynamics of the population have raised concerns about increasing health care expenditure in Japan. Therefore, it is desirable to develop an inexpensive FCM method with equivalent sensitivity to EuroFlow for detecting MRD. Aims: In this study, we analyzed the number and percentage of total plasma cells (PC), abnormal PC with EuroFlow MM-MRD and 10-color-MFC in 50 MM patients. Patients and Methods: Bone marrow samples collected from 50 MM patients were subjected to MRD detection by EuroFlow MM-MRD and 10-color-MFC simultaneously. EuroFlow MM-MRD was performed according to EuroFlow standard operating procedure. 10-color MFC was performed at BML corporation. Briefly, CD38 multiepitope FITC, CD138 V450, CD45 V500-C, CD56 PE, CD19 APC-H7, CD27 APC R700, CD81 BV605, CD117 PE-Cy7, cIgk APC and cIgl PerCP-Cy5.5 of monoclonal antibody were used according to the ICCS(International Clinical Cytometry Society) guidelines. Data were analyzed with FACSuite ver 1.2.1(Becton Dickinson) using a FACSLylic(Becton Dickinson). Wilcoxon signed-rank test was used for the comparison of paired variables. Results: The representative example of 10-color-MFC were shown in figure 1. We first compared the percentage of normal plasma cells in bone marrow. The percentage of normal plasma cells analyzed with 10-color-MFC and EuroFlow were 0.287% (range 0.001-1.0322%) and 0.257%(range0.0002-1.37%), respectively. The good correlation between them was observed (r=0.509). The percentage of myeloma cells determined with 10-color-MFC and EuroFlow were 0.0705%(range 0-0.9086%) and 0.0940% (range 0-1.3000%), respectively. Quantification of abnormal plasma cells were highly similar between 2 tests (r=0.977, figure 2). To compare the percentage of abnormal plasma cells analyzed with 10-color-MFC and EuroFlow, p-value determined with Wilcoxon signed-rank test was 0.0069 in 50 sample. However, when total bone marrow cells were 3 million cells, limit of detection (LOD) and limit of quantification (LOQ) in 10-color MFC were defined as 0.001% and 0.0017%, respectively. The correlation in samples with less than 3 million of bone marrow cells was not good (p=0.424). Only when 3 million or higher number of bone marrow cells were analyzed, better correlation is thought to be observed (p=0.0001). High concordant analytical results were observed with an overall qualitative concordance of 95%. Conclusion: Our 10-color-MFC demonstrated high sensitivity to detect MRD with good correlation and also inexpensive (about 100 dollars as of July 2019). However, 3 million or higher number of bone marrow cells is inevitable to demonstrate good correlation. In the country where high medical expenditure is not acceptable, our inexpensive MFC is considered as good alternative methods to detect MRD in MM patients. Disclosures Tsukada: Takeda Pharmaceutical Co., Ltd.: Honoraria; Janssen Pharmaceutical K.K.: Honoraria; Celgene: Honoraria; Ono Pharmaceutical: Honoraria; Sanofi: Honoraria; Kyowa Kirin: Honoraria; Chugai Pharmaceutical Co.,Ltd: Honoraria; Fujimoto Pharmaceutical: Honoraria; Ohtsuka Pharmaceutical: Honoraria; Asahi Kasei Pharma Corporation: Honoraria; MOCHIDA PHARMACEUTICAL CO., LTD.: Honoraria. Suzuki:Ono: Research Funding; BMS: Honoraria, Research Funding; Takeda: Honoraria; Janssen: Honoraria; Celgene: Honoraria.
3
van Dongen, Jacques J. M., Maurice R. G. O'Gorman, and Alberto Orfao. "EuroFlow and its activities: Introduction to the special EuroFlow issue of The Journal of Immunological Methods." Journal of Immunological Methods 475 (December 2019): 112704. http://dx.doi.org/10.1016/j.jim.2019.112704.
Full text
4
Sanoja-Flores, *Luzalba, *Bruno Paiva, Juan A. Flores-Montero, Noemi Puig, Leire Burgos, Omar García, Felipe Prosper, et al. "Next Generation Flow (NGF): A High Sensitive Technique to Detect Circulating Peripheral Blood (PB) Clonal Plasma Cells (cPC) in Patients with Newly Diagnosed of Plasma Cell Neoplasms (PCN)." Blood 126, no. 23 (December 3, 2015): 4180. http://dx.doi.org/10.1182/blood.v126.23.4180.4180.
Full textAbstract:
Abstract Introduction: Previous studies have shown that cPC can be detected in PB by conventional flow cytometry (FC) in around 70% of multiple myeloma (MM) and 37% of monoclonal gammopathy of undetermined significance (MGUS) patients at diagnosis. Its presence in MGUS has been associated with a higher risk of malignant transformation. We here investigated the utility and sensitivity of the EuroFlow-IMF NGF-MM minimal residual disease (MRD) approach for detecting circulating cPC in PB of patients with PCN. Methods: A total of 137 samples (including 71 PB and 66 bone marrow -BM- paired samples) from 71 newly-diagnosed PCN patients (37 MGUS; 21 MM; 5 SMM and 8 solitary plasmacytomas -SP-), plus 6 PB samples from healthy controls, were studied. Samples were processed following the EuroFlow Bulk Lysis Standard Operating Protocol (SOP) and stained with the EuroFlow-IMF MM MRD panel (Tube 1:CD138BV421/CD27BV510/CD38FITC/CD56PE/CD45PerCP-Cy5.5/CD19PE-Cy7/CD117APC/CD81APC-C750, and; Tube 2: identical to Tube 1 except for CyKappaAPC/CyLambdaAPC-C750). A median of 10.6 x106 events (range: 1.7 x106 - 15.7x106) were measured for PB samples using a FACSCanto II (BD Biosciences, San Jose, USA) instrument. Data were analyzed using the Infinicyt software (version 1.8.0RC6; Cytognos SL, Salamanca, Spain). Risk stratification of MGUS patients was established by the Mayo Clinic index. ROC analysis was used to define a cut-off to distinguish between MM and MGUS cases according to the percentage and absolute number of circulating PB cPC. Results: Overall, cPC were detected in the PB of all MM and SMM cases studied (100%) and more than half of MGUS patients (60%; p=0.005), while constantly absent in the eight patients with SP. Upon classifying MGUS patients according to the Mayo Clinic Index (n=32), positive PB samples were found in 25%, 62% and 73% of cases with scores of 0, 1 and 2, respectively. Median (range) percentage and absolute cPC numbers (per µL) were of 13 to 16 and 10 to 200 times lower (p<0.0001) in MGUS -0.0002% (<0.0001%-0.05450%) and 0.011 cPC/µL (range: <0.0001 cPC/µL -3.2 cPC/µL)- than in SMM -0.0026% (0.00020%-0.23%) and 0.14 cPC/µL (range: 0.022 cPC/µL - 14.58 cPC/µL) and MM -0.0033% (0.00064%-1.05%) and 2.01 cPC/µL (range: 0.043 cPC/µL -103.8 cPC/µL)-, respectively. Interestingly, a clear relationship was found between the presence of circulating cPC in PB of both MGUS, SMM and MM cases, and BM involvement by >60% of cPCs within the PC BM compartment (R2 = 0.75; n=66). The cut-off obtained to distinguish between MM and MGUS cases according to the percentage and absolute number of cPCs circulating in PB was of 0.0009% and 0.055 cPC/µL with a sensitivity of 93% and 86%, and a specificity of 75% and 75% for relative and absolute numbers, respectively. Conclusions: The EuroFlow-IMF NGF-MM MRD panel and approach are well-suited for high sensitive detection of circulating cPC in the PB of virtually every newly-diagnosed MM and SMM patient and the majority of MGUS cases, particularly among MGUS at higher risk of malignant progression; interestingly in both patients groups, the presence of PB involvement and its levels were closely associated with the degree of involvement of the BM PC compartment by cPC. * Both authors have contributed similarly to this work and they should both be considered as first author. Disclosures Paiva: EngMab AG: Research Funding; Celgene: Consultancy; Janssen: Consultancy; Millenium: Consultancy; Binding Site: Consultancy; Sanofi: Consultancy; BD Bioscience: Consultancy; Onyx: Consultancy. Puig:Janssen: Consultancy; The Binding Site: Consultancy. Mateos:Celgene: Consultancy, Honoraria; Takeda: Consultancy; Onyx: Consultancy; Janssen-Cilag: Consultancy, Honoraria. Durie:Celgene: Consultancy; Onyx: Consultancy; Takeda: Consultancy; Johnson and Johnson: Consultancy. van Dongen:BD Biosciences (cont'd): Other: Laboratory Services in the field of technical validation of EuroFlow-OneFlow antibody tubes in dried format. The Laboratory Services are provided by the Laboratory of Medical Immunology, Dept. of Immunology, Erasmus MC, Rotterdam, NL; Cytognos: Patents & Royalties: Licensing of IP on Infinicyt software, Patents on EuroFlow-based flowcytometric Diagnosis and Classification of hematological malignancies, Patents on MRD diagnostics, and Patents on PID diagnostics. ; Cytognos (continued): Patents & Royalties: Royalty income for EuroFlow Consortium. The Infinicyt software is provided to all EuroFlow members free-of-charge.Licensing of Patent on detection of IgE+ B-cells in allergic diseases. Royalties for Dept. of Immunology, Erasmus MC, Rotterdam, NL; DAKO: Patents & Royalties: Licensing of IP and Patent on Split-Signal FISH. Royalties for Dept. of Immunology, Erasmus MC, Rotterdam, NL; InVivoScribe: Patents & Royalties: Licensing of IP and Patent on BIOMED-2-based methods for PCR-based Clonality Diagnostics.. Royalty income for EuroClonality-BIOMED-2 Consortium ; Immunostep: Patents & Royalties: Licensing of IP and Patents on immunobead-based dection of fusion proteins in acute leukemias and other tumors. Royalties for Dept. of Immunology, Erasmus MC and for EuroFlow Consortium ; BD Biosciences: Other: Educational Services: Educational Lectures and Educational Workshops (+ related travelling costs). The lectures and workshops fully focus on the scientific achievements of the EuroFlow Consortium (No advertisement of products of BD Biosciences). , Patents & Royalties: Licensing of IP and Patent on EuroFlow-based flowcytometric Diagnosis and Classification of hematological malignancies; Royalty income for EuroFlow Consortium.; Roche: Consultancy, Other: Laboratory Services in the field of MRD diagnostics, provided by the Laboratory of Medical Immunology, Dept. of Immunology, Erasmus MC, Rotterdam, NL.. San Miguel:Janssen-Cilag: Honoraria; Onyx: Honoraria; Millennium: Honoraria; Bristol-Myers Squibb: Honoraria; Celgene: Honoraria; Novartis: Honoraria; Sanofi-Aventis: Honoraria.
5
Kalina, Tomas, Nadezda Brdickova, Hana Glier, Paula Fernandez, Marieke Bitter, Juan Flores-Montero, Jacques J. M. van Dongen, and Alberto Orfao. "Frequent issues and lessons learned from EuroFlow QA." Journal of Immunological Methods 475 (December 2019): 112520. http://dx.doi.org/10.1016/j.jim.2018.09.008.
Full text
6
Roshal, Mikhail, Juan A. Flores-Montero, Qi Gao, Maesa Koeber, Jessica Wardrope, Brian G. M. Durie, Ahmet Dogan, Alberto Orfao, and Ola Landgren. "MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods." Blood Advances 1, no. 12 (May 3, 2017): 728–32. http://dx.doi.org/10.1182/bloodadvances.2016003715.
Full text
7
Takamatsu, Hiroyuki, Takeshi Yoroidaka, Takeshi Yamashita, Ryoichi Murata, Mikio Ueda, Shinji Nakao, and Kosei Matsue. "Comparison of Minimal Residual Disease Detection between the Manual and Automated Gating Strategies of Euroflow Next-Generation Flow in Patients with Multiple Myeloma." Blood 134, Supplement_1 (November 13, 2019): 3083. http://dx.doi.org/10.1182/blood-2019-122398.
Full textAbstract:
Background: The rate of complete response (CR) in multiple myeloma (MM) has dramatically increased because of the development of novel agents. In addition, the development of methods for measuring minimal residual disease (MRD), such as multiparameter flow cytometry and next-generation sequencing, has made it possible to stratify CR patients according to the MRD extent. EuroFlow next-generation flow (EuroFlow-NGF) is considered one of the gold standard methods for evaluating the negative status of MRD in MM. The automated gating strategy of EuroFlow-NGF has been shown to detect MRD as accurately as the manual gating strategy by experts. Oberle et al. (Haematologica, 2017) have found that daratumumab persisted on the surface of myeloma cells treated with it and that the anti-CD38 multi-epitope antibody used in EuroFlow-NGF has partial cross-reactivity with daratumumab, leading to generally lower mean fluorescence intensities of CD38. Therefore, MRD levels may have been underestimated in patients who were treated with anti-CD38 monoclonal antibodies (mAbs) using the automated gating strategy, leading to inappropriate management of the patients. Because no studies have examined the correlation of MRD extent between the manual and automated gating strategies in patients with MM who have received anti-CD38 mAbs, we compared MRD detection between the two gating strategies of EuroFlow-NGF in patients with MM. Methods: The study included bone marrow samples from 51 patients with MM (27 male and 24 female patients), including 13 patients treated with anti-CD38 mAb (12 treated with daratumumab and 1 treated with isatuximab). The median patient age was 70 years (range, 32-92 years) at MRD assessment. The disease statuses at MRD assessment were stringent CR in 26 patients (51%), CR in 7 (14%), very good partial response in 13 (26%), partial response in 1 (2%), and progressive disease in 4 (8%). The sample preparation protocol, Ab panel, and automated gating strategy of EuroFlow-NGF have been reported previously (Flores-Montero et al. Leukemia 2017). Briefly, we performed the EuroFlow-NGF method, which involved ammonium chloride-based bulk lysis, followed by surface staining using antibodies against CD138-BV421, CD27-BV510, CD38 multiepitope (ME)-FITC, CD56-PE, CD45-PerCP Cy5.5, CD19-PECy7, CD117-APC, and CD81-APC C750 in tube 1 and surface/intracellular staining using antibodies against CD138-BV421, CD27-BV510, CD38 ME-FITC, CD56-PE, CD45-PerCP Cy5.5, CD19-PECy7, CD117-APC, CD81-APC C750, cytoplasmic (cy) Igκ-APC, and cyIgλ-APC C750 after permeabilization in tube 2. For data analysis, events from both eight-color tubes (tubes 1 and 2) were merged, and the values of all parameters per tube were mathematically calculated using the merge and calculation functions of Infinicyt software (Cytognos SL, Salamanca, Spain). Automatic identification and enumeration of total plasma cells (tPCs) and abnormal plasma cells (MRD) were performed using the automatic gating function of Infinicyt software as described previously (Flores-Montero et al. Leukemia 2017). We compared the total nucleated cell number, tPC ratio, and MRD ratio between the manual (by experts) and automated gating strategies of EuroFlow-NGF. Results: In patients with MM who did not receive any anti-CD38 mAb therapy, we observed high correlations for both the tPC (r = 0.959, P < 0.0001) (Figure A) and MRD (r = 0.974, P < 0.0001) (Figure B) ratios between the manual and automated gating strategies of EuroFlow-NGF. On the other hand, in patients with MM who received anti-CD38 mAb therapy, we did not observe good correlations for both the tPC (r = 0.349, P = 0.2) (Figure A) and MRD (r = 0.292, P = 0.3) (Figure B) ratios between the two strategies owing to a lower fluorescence intensity of CD38 on PCs. In addition, when the MRD threshold was set to 10-5, the discordance of MRD positivity/negativity between the two strategies was significantly higher in patients who received anti-CD38 mAb therapy than in those who did not receive anti-CD38 mAb therapy [4/13 (31%) vs. 1/38 (3%), P = 0.012]. Conclusion: Although the automated gating strategy of EuroFlow-NGF could be a viable alternative to the manual strategy for the assessment of MRD in MM, we may have to utilize the manual strategy to obtain precise MRD results for patients with MM who received anti-CD38 mAbs. Figure Disclosures Takamatsu: Celgene: Consultancy, Honoraria, Research Funding; Bristol-Myers Squibb: Honoraria, Research Funding; Ono pharmaceutical: Honoraria, Research Funding; CSL Behring: Research Funding; SRL: Consultancy, Research Funding; Janssen Pharmaceutical: Consultancy, Honoraria; Sanofi: Consultancy, Honoraria; Takeda Pharmaceutical Company Limited: Honoraria; Fujimoto Pharmaceutical: Honoraria; Becton, Dickinson and Company: Honoraria; Abbvie: Consultancy; Daiichi-Sankyo Company: Honoraria. Yoroidaka:Ono Pharmaceutical: Honoraria. Yamashita:Janssen Pharmaceutical K.K.: Honoraria; Daiichi-Sankyo Company: Honoraria; Kyowa Kirin: Honoraria; Chugai Pharmaceutical Co.,Ltd: Honoraria; TEIJIN PHARMA LIMITED: Honoraria; Takeda Pharmaceutical Company Limited: Honoraria; Bristol-Myers Squibb: Honoraria; Ono Pharmaceutical: Honoraria; Celgene: Honoraria. Murata:Celgene: Honoraria; Ono pharmaceutical: Honoraria. Nakao:Daiichi-Sankyo Company, Limited: Honoraria; Janssen Pharmaceutical K.K.: Honoraria; SynBio Pharmaceuticals: Consultancy; Ohtsuka Pharmaceutical: Honoraria; Celgene: Honoraria; Ono Pharmaceutical: Honoraria; Novartis Pharma K.K: Honoraria; Bristol-Myers Squibb: Honoraria; Takeda Pharmaceutical Company Limited: Honoraria; Chugai Pharmaceutical Co.,Ltd: Honoraria; Kyowa Kirin: Honoraria; Alaxion Pharmaceuticals: Honoraria. Matsue:Novartis Pharma K.K: Honoraria; Ono Pharmaceutical: Honoraria; Takeda Pharmaceutical Company Limited: Honoraria; Celgene: Honoraria; Janssen Pharmaceutical K.K.: Honoraria.
8
Szczepański, T. "Nowoczesna diagnostyka i monitorowanie ostrych białaczek wg standardów EuroFlow." Acta Haematologica Polonica 46 (September 2015): 1. http://dx.doi.org/10.1016/j.achaem.2015.07.016.
Full text
9
Takamatsu, Hiroyuki, Naoki Takezako, Rachel K. Wee, Takeshi Yoroidaka, Takeshi Yamashita, Ryoichi Murata, Kosei Matsue, and Shinji Nakao. "Comparison of Minimal Residual Disease Detection in Autografts of Patients with Multiple Myeloma between 8-Color Multiparameter Flow Cytometry (EuroFlow) and Next-Generation Sequencing." Blood 132, Supplement 1 (November 29, 2018): 258. http://dx.doi.org/10.1182/blood-2018-99-111250.
Full textAbstract:
Abstract Background: Autologous stem cell transplantation (ASCT) in conjunction with novel therapeutic drugs can dramatically improve response rates and the prognosis of patients with multiple myeloma (MM). However, most patients with MM are considered to be incurable, and relapse owing to minimal residual disease (MRD) is the main cause of death among these patients. Therefore, new technologies to assess deeper responses are required. Next-generation sequencing (NGS) and multiparameter flow cytometry (MFC) methods have been used to assess MRD. However, the lack of standardization of conventional MFC approaches has had a negative impact on its reproducibility. Recently, a next-generation MFC method (EuroFlow, NGF) has been developed by the EuroFlow Consortium and the International Myeloma Foundation (IMF) for a highly sensitive and standardized detection of MRD in MM. Aims: To compare the prognostic value of MRD detection in autografts in MM between NGS (Adaptive) and 8-color MFC method (EuroFlow, NGF), and also MRD levels between fresh and cryopreserved autografts. Methods: A total of 39 newly-diagnosed MM patients who underwent ASCT were enrolled in this study. Median age 60 at ASCT (range 41-69); males 22, females 17; ISS 1 (n=10), 2 (n=19), 3 (n=10). 10 patients showed high-risk chromosomal abnormalities (t(4;14) (n=9), del17p & t(4;14) (n=1)). The induction regimen was bortezomib-based chemotherapy. All patients received melphalan 200 mg/sqm as conditioning regimen before ASCT. 34 of 39 (87%) patients received maintenance therapy until progressive disease. The best response post-ASCT was as follows: 23sCR, 2CR, 12VGPR, 2PR. 39 autografts, one from each MM patient, were analyzed using NGF and NGS methods. The NGF method was based on a standardized lyse-wash-and-stain sample preparation protocol, the measurement of high numbers of cells and an optimized 8-color, 2-tubes, antibody panel, for accurate identification of plasma cells (PCs) and discrimination between phenotypically aberrant (aPC) and normal PC (nPC) (J Flores-Montero et al., Leukemia 2017). NGS-based MRD assessment was performed using Adaptive's standardized NGS-MRD Assay (Seattle, WA) (Martinez-Lopez et al., Blood 2014). To assess the correlation of MRD levels between fresh and cryopreserved autografts using NGF, 6 additional MM patients' autografts were used. Results: MRD levels in all 39 autografts were assessed using EuroFlow, while those in 32 of 39 (82%) were assessed with NGS due to limited availability of material for calibration. We identified abnormal plasma cells (aPC) in autografts based on multivariate analysis of individual cells from each patient (e.g. CD56+, CD19-, CyIgκ+, CD117+). Since there was a good correlation in MRD levels between fresh and thawed frozen autografts detected by EuroFlow (R=0.943, P=0.02), we assessed the MRD levels in thawed frozen autografts. For the MM MRD in autografts, the events from tube 1 and tube 2 were combined and a median of 7.3×106 (range: 2.2×106-37.6×106) events was acquired. The sensitivity of EuroFlow was 1×10-5-2×10-6 while that of NGS was 10-7 due to the high number of DNA derived from autografts (Takamatsu et al., Ann Oncol 2017). 21 of 39 (54%) cases were MRD positive by 8-color MFC while 22 of 32 (69%) cases were MRD positive by NGS. The correlation of MRD levels between 8-color MFC and NGS was relatively high (Fig. 1A). MRD negative by NGF (MRDMFC (-)) cases tended to show better PFS than MRDMFC (+) cases (P=0.145) (Fig. 1B) while MRD negative by NGS (MRDNGS (-)) cases showed significantly better PFS than MRDNGS (+) cases (P=0.03) (Fig. 1C). Furthermore, MRDMFC (-) MRDNGS (-) cases showed significantly better PFS than MRDMFC (-) MRDNGS (+) cases (P=0.01), but the PFS of MRDMFC (-) MRDNGS (+) cases was not different from that of MRDMFC (+) MRDNGS (+) cases (P=0.70). MRDMFC (-) and MRDNGS (-) cases showed better OS than MRDMFC (+) (P=0.14) and MRDNGS (+) (P=0.08) cases, respectively. Conclusions: Although EuroFlow is a fast and accurate method for detecting MRD of MM in autografts, in this study the NGS platform had a higher sensitivity and prognostic value than EuroFlow. The homogenous nature of the mobilized autograft relative to the focal nature of myeloma in bone marrow might provide a better sample to assess MRD. Figure 1. Figure 1. Disclosures Takamatsu: Celgene: Honoraria, Research Funding; Ono: Research Funding; Bristol-Myers Squibb: Research Funding; Janssen: Honoraria. Nakao:Novartis: Honoraria; Kyowa Hakko Kirin Co., Ltd.: Honoraria; Alexion Pharmaceuticals, Inc.: Consultancy, Honoraria.
10
Flores-Montero, Juan A., Bruno Paiva, Luzalba Sanoja-Flores, Noemi Puig, Omar García, Sebastian Böttcher, José J. Pérez-Morán, et al. "Next Generation Flow (NGF) for High Sensitive Detection of Minimal Residual Disease (MRD) in Multiple Myeloma (MM)." Blood 126, no. 23 (December 3, 2015): 367. http://dx.doi.org/10.1182/blood.v126.23.367.367.
Full textAbstract:
Abstract Introduction: The clinical and prognostic utility of MRD monitoring in MM bone marrow (BM) by first generation (4-6-color) flow cytometry (flow-MRD), has been now demostrated for more than a decade. Thereby, flow-MRD is considered to be a well-suited technique for MRD monitoring in MM, due to its high applicability and specificity, and its broad availability in diagnostic laboratories. However, recent results have confirmed that 1st generation flow-MRD has a lower sensitivity than molecular techniques such as allele-specific oligonucleotyde (ASO)-PCR and next generation sequencing (NGS); in addition, the lack of standardization of conventional flow-MRD approaches, also has a negative impact on its reproducibility. Here we report on the validation of the next generation flow (NGF)-MRD approach developed by the EuroFlow Consortium and the International Myeloma Foundation (IMF) for ultrasensitive and standardized detection of MRD in MM. Methods: A total of 275 BM samples were included in the study: 1) a group of 31 normal/reactive and 63 diagnostic MM BM samples were evaluated to identify the most efficient candidate markers for the NGF panel, using a multivariate analysis-based approach; 2) next, a total of 181 BM samples from 15 healthy donors (HD), 36 MGUS, 15 MM and 3 solitary plasmacytoma (SP) patients studied at diagnosis, plus 112 MM follow-up samples, most of which (n=71) corresponded to BM samples from MM patients in very good partial response, complete remission (CR) or stringent CR were analyzed. These samples were evaluated by the EuroFlow-IMF NGF-MRD method. The method was based on a (standardized) lyse-wash-and-stain sample preparation protocol, the measurement of high numbers of BM cells (≥5x106 cells/tube) and an optimized 8-color, 2-tubes, antibody panel, for accurate identification of BM plasma cells (PCs) and discrimination between phenotypically aberrant (aPC) and normal PC (nPC): tube 1: CD138BV421 CD27BV510 CD38FITC CD56PE CD45PerCP Cy5.5 CD19PE Cy7 CD117APC CD81APC C750, and; tube 2: identical to tube 1 except for cytoplasmic (Cy) Immunoglobulin (Ig) kAPC/CyIglAPC C750). Results obtained with the NGF-MRD MM method in the 71 VGPR, CR and sCR samples, were then compared with a 2nd generation (routine) 8-color flow-MRD approach which involved a single 8-color combination staining for the same markers described above for tube 1, but in the absence of full optimization of the positions for the antibody-fluorochrome conjugates and no selection for treatment-independent antibody CD38 clones. In a subset of 16 of these 71 MRD samples in which enough material was available, comparison with NGS was also performed in parallel. Results: In all MGUS, MM and SP cases analyzed at diagnosis, aPC showed aberrant phenotypes vs. nPC from HD BM, based on multivariate analysis of individual cells from each of the patients against a reference data base of normal/reactive PCs (100% applicability). For the MM MRD BM samples, a median of 9.8x106 (range: 2.4-15.3) events were acquired (tube 1 plus 2) vs. 1x106 (range: 0.03-5) events for the 2nd generation flow-MRD approach with an (estimated) 10 times lower limit of detection and 10 times lower limit of quantitation of 3x10-6 and 5x10-6 vs. 3x10-5 and 5x10-5 for the NGF-MRD vs. the 2nd generation flow-MRD approaches, respectively. This led to a higher rate of MRD+ samples with the NGF-MRD method: 14/48 (29%) cases that were flow-MRD-negative with the 2nd generation 8-color flow-MRD method became MRD+ (median percentage of residual aPC of 0.0007%; range: 0.0002 to 0.02%) (Figure 1A). In contrast, 4/38 (11%) samples were negative by NGF, while positive by 2nd generation flow-MRD; one of these four proved to be MRD-negative by cytoplasmic immunoglobulin light chain restriction analysis. Further comparison of NGF vs NGS showed 9 of the 16 samples evaluable were MRD-negative by NGS; from them, one third (3/9) were positive by NGF with a median number of residual aPCs of 0.005% (range: 0.0002-0.006%) (Figure 1B). Conclusions: The EuroFlow-IMF NGF-MRD approach provides a fast, highly applicable, ultrasensitive, standardized and accurate approach for the assessment of MRD in BM samples from MM patients and overcomes the current limitations of both 1st and 2nd generation flow-MRD approaches; preliminary results showed higher sensitivity than NGS. Figure 1. Figure 1. Disclosures Paiva: Sanofi: Consultancy; Binding Site: Consultancy; EngMab AG: Research Funding; BD Bioscience: Consultancy; Millenium: Consultancy; Onyx: Consultancy; Celgene: Consultancy; Janssen: Consultancy. Puig:Janssen: Consultancy; The Binding Site: Consultancy. Mateos:Janssen-Cilag: Consultancy, Honoraria; Takeda: Consultancy; Celgene: Consultancy, Honoraria; Onyx: Consultancy. San Miguel:Sanofi-Aventis: Honoraria; Novartis: Honoraria; Millennium: Honoraria; Janssen-Cilag: Honoraria; Celgene: Honoraria; Bristol-Myers Squibb: Honoraria; Onyx: Honoraria. Durie:Celgene: Consultancy; Onyx: Consultancy; Takeda: Consultancy; Johnson & Johnson: Consultancy. van Dongen:Immunostep: Patents & Royalties: Licensing of IP and Patents on immunobead-based dection of fusion proteins in acute leukemias and other tumors. Royalties for Dept. of Immunology, Erasmus MC and for EuroFlow Consortium ; BD Biosciences (cont'd): Other: Laboratory Services in the field of technical validation of EuroFlow-OneFlow antibody tubes in dried format. The Laboratory Services are provided by the Laboratory of Medical Immunology, Dept. of Immunology, Erasmus MC, Rotterdam, NL; Cytognos: Patents & Royalties: Licensing of IP on Infinicyt software, Patents on EuroFlow-based flowcytometric Diagnosis and Classification of hematological malignancies, Patents on MRD diagnostics, and Patents on PID diagnostics.; Cytognos (continued): Patents & Royalties: Royalty income for EuroFlow Consortium. The Infinicyt software is provided to all EuroFlow members free-of-charge. Licensing of Patent on detection of IgE+ B-cells in allergic diseases. Royalties for Dept. of Immunology, Erasmus MC, Rotterdam, NL; DAKO: Patents & Royalties: Licensing of IP and Patent on Split-Signal FISH. Royalties for Dept. of Immunology, Erasmus MC, Rotterdam, NL; InVivoScribe: Patents & Royalties: Licensing of IP and Patent on BIOMED-2-based methods for PCR-based Clonality Diagnostics. Royalty income for EuroClonality-BIOMED-2 Consortium; BD Biosciences: Other: Educational Services: Educational Lectures and Educational Workshops (+ related travelling costs). The lectures and workshops fully focus on the scientific achievements of the EuroFlow Consortium (No advertisement of products of BD Biosciences)., Patents & Royalties: Licensing of IP and Patent on EuroFlow-based flowcytometric Diagnosis and Classification of hematological malignancies; Royalty income for EuroFlow Consortium.; Roche: Consultancy, Other: Laboratory Services in the field of MRD diagnostics, provided by the Laboratory of Medical Immunology, Dept. of Immunology, Erasmus MC, Rotterdam, NL..
Dissertations / Theses on the topic "Euroflow"
1
Magalhães, João. "O Batalhão de Infantaria do Battlegroup da União Europeia." Master's thesis, Academia Militar. Direção de Ensino, 2012. http://hdl.handle.net/10400.26/8500.
Full textAbstract:
O presente Trabalho de Investigação Aplicada é subordinado ao tema “O Batalhão de Infantaria do Battlegroup da União Europeia”, visando esclarecer quais as capacidades e as características que um Batalhão necessita para integrar um Battlegroup.
Tem como objetivo a realização de um estudo que possibilite dar a conhecer qual a
unidade de Infantaria escalão Batalhão que se encontra nas melhores condições para se formar num Battlegroup.
Para a realização do estudo em questão, efetuou-se uma exaustiva pesquisa bibliográfica, que serviu de base para a elaboração de um questionário com que se pretendia verificar as hipóteses de resposta para a questão central levantada: “Qual o Batalhão de Infantaria mais adequado para constituir o Battlegroup?”. Ressalve-se que o método que foi utilizado na realização deste trabalho foi a análise qualitativa, sob a forma de estudo de caso.
Após a análise dos resultados, concluiu-se que a melhor resposta reside numa
unidade de infantaria ligeira, que possua uma grande capacidade de projeção e material e equipamento que confiram real proteção e mobilidade, podendo conter uma organização que lhe confira maior flexibilidade, através da conjugação de várias tipologias de meios e incluindo outras capacidades para aumentar a sua capacidade de emprego.Abstract This Investigation paper on the theme “The Infantry Battalion of the European Union Battlegroup” aims to clarify the capabilities and features of a maneuver battalion sized unit required to integrate a BG. The aim is to carry out a study directed to identify which Infantry Battalion is more suitable to integrate a BG. To conduct this study, I went through an exhaustive bibliographical research, which was the basis for the development of a questionnaire intended to verify the hypotheses related with the main question raised: “Which Infantry Battalion is more appropriate for the Battlegroup?” The method used was a qualitative analysis, under a case study format. After analyzing the results it is concluded that a light infantry unit with a strong deployment capability, and material and equipment providing protection and mobility its the best answer, organized in order to allow more flexibility of employm ent, through combinations of several different types of assets, including suportting capabilities to increase its own potential may contain an organization that confers greater flexibility, by combining various types of media and other capabilities including the ability to increase employment.
2
Santos, Diego Jatobá dos. "INFLUÊNCIA DA TURBULÊNCIA INTERMITENTE NA ESTIMATIVA DOS FLUXOS DE CO2 NOTURNOS." Universidade Federal de Santa Maria, 2012. http://repositorio.ufsm.br/handle/1/10265.
Full textAbstract:
Coordenação de Aperfeiçoamento de Pessoal de Nível SuperiorNocturnal turbulent flux data are analysed, initially for two experimental sites in Brazil, and later for a large variety of biomes. In such case, a wide dataset, originated from more than a hundred flux stations scattered over Europe and the Americas is used. Emphasis is given to important aspects associated to the occurrence of intermittent turbulence and its implications for CO2 nocturnal flux estimates. Intermittency factors (IF) for CO2 and sensible heat fluxes are determined for the set of stations. In most cases, there was agreement between the results for CO2 and sensible heat, specially for those stations that were less intermittent, on average. A larger number of stations showed low IF for CO2 than for sensible heat fluxes. CO2 flux intermittency was significantly larger over higher canopies than over savannas or crops, while the same difference is smaller for the sensible heat flux. An investigation on the CO2 flux dependence on the temporal variability of the turbulence intensity is carried on . The main purpose of such an anlysis is identifying whether ther is CO2 storage during low turbulence periods and if such accumulated CO2 affects the fluxes in subsequent periods. In the vast majority of the stations, the classical pattern of NEE decreasing as u* tends to zero is observed. The hypothesis of the present study is that such NEE decrease under calm situations does not necessarily imply on flux lost by the eddy covariance technique, but that it may have not been properly captured by the CO2 storage term, being later measured in subsequent turbulent situations. Therefore, the present study has as the main goal identifying a potential problem in the correcting procedure commonly applied for low turbulent periods. Specifically, it is important to analyse whether the periods whose data are being replaced are not suceeded by others for which there is flux excess, characterizing, therefore, an excessive correction. Results indicate that there is a large quantity os stations for which the fluxes are independent on turbulence intensity variability, with evidences that the observed reduction during calm periods is compensated when it gets turbulent. In such cases, it is possible that corrections commonly used for calm conditions are, indeed, excessive. .
Dados de fluxos turbulentos noturnos são analisados, primeiramente, para dois sítios experimentais no Brasil e uma posterior expansão dessas análises é realizada para uma grande variedade de biomas, utilizando para tanto, um conjunto amplo de dados originados de mais de uma centena de estações de fluxos, espalhadas nas Américas e na Europa. A ênfase é dada aos aspectos importantes associados à ocorrência de turbulência intermitente e suas implicações para as estimativas de fluxos turbulentos noturnos de CO2. Fatores de intermitência (FI) dos fluxos de CO2 e de calor sensível são definidos e quantificados para o conjunto de estações. Na maioria dos casos, houve concordância entre os comportamentos obtidos para o fluxo de CO2 e de calor sensível, especialmente nas estações que na média apresentaram condições pouco intermitentes. Um número maior de estações apresentaram valores reduzidos de FI para fluxo de CO2 do que para o de calor sensível. A intermitência dos fluxos de CO2 se mostrou significativamente maior sobre estações de maior altura do dossel (florestas) do que sobre estações de savana ou agrícolas, enquanto que a mesma diferença é muito mais reduzida para os fluxos de calor sensível. Uma investigação da dependência dos fluxos de CO2 em relação à variabilidade temporal de turbulência ao longo da noite foi realizada. O propósito principal da análise é identificar se há acúmulo de CO2 em períodos pouco turbulentos e se este CO2 acumulado afeta os fluxos em períodos subsequentes. Na imensa maioria das estações, se observou um padrão clássico de NEE diminuindo conforme u* tende a zero. É hipótese do presente trabalho que o decréscimo de NEE em situações calmas não necessariamente indica fluxo não contabilizado pelo método da covariância dos vórtices, mas que este pode não ter sido propriamente capturado pelo termo de armazenamento, sendo posteriormente capturado pelo sensor em situações turbulentas subsequentes. Desta forma, o presente estudo tem como precípuo intento, contribuir no sentido de identificar um potencial problema na utilização das técnicas de correção de dados utilizadas para os períodos com pequena intensidade turbulenta. Especificamente, é importante analisar se os períodos que estão tendo seus dados substituídos não são sucedidos por outros em que houve excesso de fluxo, caracterizando, desta forma, uma correção excessiva. Os resultados indicam que há uma grande quantidade de estações para as quais os fluxos são independentes da variabilidade da intensidade turbulenta, havendo indicações que a redução observada em períodos calmos seja compensada em intervalos turbulentos. Nesses casos, é possível que correções comumente usadas para a correção de fluxos em condições calmas sejam excessivas.
3
Hagemann, Frank. "Strategic planning for comprehensive security in the European Union's military operations EUROFOR RD Congo, EUROF Tchad/RCA, and EUNAVFOR Somalia /." Thesis, Monterey, California : Naval Postgraduate School, 2010. http://edocs.nps.edu/npspubs/scholarly/theses/2010/Jun/10Jun%5FHagemann.pdf.
Full textAbstract:
Thesis (M.A. in Security Studies (Europe and Eurasia))--Naval Postgraduate School, June 2010.Thesis Advisor(s): Abenheim, Donald ; Yost, David S. "June 2010." Description based on title screen as viewed on July 14, 2010. Author(s) subject terms: European Union, comprehensive security, strategic planning, European security and defense policy, ESDP, common security and defense policy, CSDP, military operations, crisis management, EUFOR RD Congo, EUFOR Tchad/RCA, EUNAVFOR Somalia Includes bibliographical references (p. 83-98). Also available in print.
4
Cima, Matteo. "L'euroletto bulgaro: analisi comparata di un corpus di direttive europee e di leggi nazionali di recepimento." Master's thesis, Alma Mater Studiorum - Università di Bologna, 2018. http://amslaurea.unibo.it/15342/.
Full textAbstract:
В резултат от работата на Главна дирекция „Писмени преводи“ на Европейската комисия възниква един значителен обем от правни текстове, отличаващи се с език, различен от юридическия професиолект на съответната държава членка. Тази специфична езикова формация е известна под името евролект и нейното съществуване е доказано за близо половината от официалните езици на Европейския съюз. Целта на настоящото изследване беше да се определи доколко въпросното явлениe засяга и българския език, т.е. може ли да се говори за български евролект. Затова беше направен качествен съпоставителен анализ на два корпуса, състоящи се съответно от 10 директиви и 10 национални закона, на следните нива: лексика, именна морфология, глаголна морфология, фраземи, синтаксис, текстуалност, правопис и пунктуация. Анализът показа, че макар да съществуват определени системни различия между двата корпуса, те не дават основание да се говори с категоричност за съществуването на български евролект. В заключение ние считаме, че за да се потвърди или отхвърли хипотезата за съществуването му е необходимо да се извърши допълнителна работа по увеличаване на корпусите и включване на количествен анализ на изследваните параметри по нива.
5
Šinkorová, Vendula. "Vývoj metody 8-mi barevného cytometrického testování pacientů s primárním imunodeficitem." Master's thesis, 2014. http://www.nusl.cz/ntk/nusl-336884.
Full textAbstract:
Primary immunodeficiencies represent a heterogeneous group of hereditary immune system malfunctions with very variable causes and symptoms. Multiparametric flow cytometry has become an important tool in primary immunodeficiency diagnostics and research because it provides detailed information on the phenotype of individual immune cells and their proportions in circulation. We have developed a complex monoclonal antibody panel composed of five eight-color tubes which is designed for immunophenotyping of basic lymphocyte subsets and further analysis of B and T cell subpopulations. We have optimized and standardized the panels so they will identify any changes originating from primary immunodeficiencies and provide comparable data on the level of cooperation between more laboratories. This was achieved by cooperation of six European research facilities which are all parts of the Euroflow consortium. The panels have been validated both on peripheral blood samples from healthy donors and patients with either gentically defined primary immunodeficiency or common variable immunodeficiency. Keywords: T lymphocyte, B lymphocyte, primary immunodeficiency, flow cytometry, immunophenotyping, Euroflow, optimization, standardization
Books on the topic "Euroflow"
1
European, Symposium Euroflex (1993 Lisbon Portugal). Flexible pavements: Proceedings of the European Symposium Euroflex 1993 : Lisbon, Portugal, 20-22 September 1993. Rotterdam: A.A. Balkema, 1996.
Find full text
2
Eurofood Conference (1st 1990 Brussels). Food quality in the single European market: The First Eurofood Conference, 5-6 April 1990. London: Agra Europe, 1990.
Find full text
3
Sandro, Amaducci, ed. Eurofood monitor: European Community legislation on foodstuffs. Tunbridge Wells: Agra Europe (London) Ltd, 1990.
Find full text
4
Sandro, Amaducci, and Agra Europe, eds. Eurofood monitor: European Community legislation on foodstuffs. Tunbridge Wells: Agra Europe (London) Ltd, 1990.
Find full text
5
Biel, Lucja. Lost in the Eurofog: The Textual Fit of Translated Law. Lang GmbH, Internationaler Verlag der Wissenschaften, Peter, 2014.
Find full text
6
Biel, Lucja. Lost in the Eurofog: The Textual Fit of Translated Law. Lang GmbH, Internationaler Verlag der Wissenschaften, Peter, 2014.
Find full text
7
Biel, Lucja. Lost in the Eurofog: The Textual Fit of Translated Law. Lang Publishing, Incorporated, Peter, 2014.
Find full text
8
Biel, Lucja. Lost in the Eurofog: The Textual Fit of Translated Law. Lang GmbH, Internationaler Verlag der Wissenschaften, Peter, 2014.
Find full text
9
Biel, Lucja. Lost in the Eurofog: The Textual Fit of Translated Law. Lang GmbH, Internationaler Verlag der Wissenschaften, Peter, 2014.
Find full text
10
Biel, Lucja. Lost in the Eurofog : the Textual Fit of Translated Law: Second Revised Edition. Lang GmbH, Internationaler Verlag der Wissenschaften, Peter, 2017.
Find full textBook chapters on the topic "Euroflow"
1
Burgos, Leire, and Bruno Paiva. "Retracted Chapter: EuroFlow-Based Next-Generation Flow Cytometry for Detection of Circulating Tumor Cells and Minimal Residual Disease in Multiple Myeloma." In Methods in Molecular Biology, 15–34. New York, NY: Springer New York, 2018. http://dx.doi.org/10.1007/978-1-4939-7865-6_2.
Full text
2
Burgos, Leire, and Bruno Paiva. "Retraction Note to: EuroFlow-Based Next-Generation Flow Cytometry for Detection of Circulating Tumor Cells and Minimal Residual Disease in Multiple Myeloma." In Methods in Molecular Biology, E1. New York, NY: Springer New York, 2018. http://dx.doi.org/10.1007/978-1-4939-7865-6_16.
Full text
3
Dalgic, Tevfik, and Harry Bloemen. "Internationalisation of the Eurofood Retail Sector with Special Reference to Foreign Market Entry Modes." In Developments in Marketing Science: Proceedings of the Academy of Marketing Science, 176–77. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-17323-8_43.
Full text
4
Benmimoun, Mohamed, Andreas Pütz, Adrian Zlocki, and Lutz Eckstein. "euroFOT: Field Operational Test and Impact Assessment of Advanced Driver Assistance Systems: Final Results." In Lecture Notes in Electrical Engineering, 537–47. Berlin, Heidelberg: Springer Berlin Heidelberg, 2012. http://dx.doi.org/10.1007/978-3-642-33805-2_43.
Full text
5
Valentini, R. "EUROFLUX: An Integrated Network for Studying the Long-Term Responses of Biospheric Exchanges of Carbon, Water, and Energy of European Forests." In Fluxes of Carbon, Water and Energy of European Forests, 1–8. Berlin, Heidelberg: Springer Berlin Heidelberg, 2003. http://dx.doi.org/10.1007/978-3-662-05171-9_1.
Full text
6
Bellotti, Francesco, Riccardo Berta, Alessandro De Gloria, and Massimiliano Margarone. "Widely Usable User Interfaces on Mobile Devices with RFID." In Mobile Computing, 3387–403. IGI Global, 2009. http://dx.doi.org/10.4018/978-1-60566-054-7.ch249.
Full textAbstract:
Diffusion of radio frequency identification (RFID) promises to boost the added value of assistive technologies for mobile users. Visually impaired people may benefit from RFID-based applications that support users in maintaining “spatial orientation” (Mann, 2004) through provision of information on where they are, and a description of what lies in their surroundings. To investigate this issue, we have integrated our development tool for mobile device, (namely: MADE, Bellotti, Berta, De Gloria, & Margarone, 2003), with a complete support for RFID tag detection, and implemented an RFID-enabled location-aware tour-guide. We have evaluated the guide in an ecological context (fully operational application, real users, real context of use (Abowd & Mynatt, 2000)) during the EuroFlora 2006 international exhibition (EuroFlora). In this chapter, we describe the MADE enhancement to support RFID-based applications, present the main concepts of the interaction modalities we have designed in order to support visually impaired users, and discuss results from our field experience.
7
Bellotti, Francesco, Riccardo Berta, Alessandro De Gloria, and Massimiliano Margarone. "Widely Usable User Interfaces on Mobile Devices with RFID." In Handbook of Research on User Interface Design and Evaluation for Mobile Technology, 657–72. IGI Global, 2008. http://dx.doi.org/10.4018/978-1-59904-871-0.ch039.
Full textAbstract:
Diffusion of radio frequency identification (RFID) promises to boost the added value of assistive technologies for mobile users. Visually impaired people may benefit from RFID-based applications that support users in maintaining “spatial orientation” (Mann, 2004) through provision of information on where they are, and a description of what lies in their surroundings. To investigate this issue, we have integrated our development tool for mobile device, (namely: MADE, Bellotti, Berta, De Gloria, & Margarone, 2003), with a complete support for RFID tag detection, and implemented an RFID-enabled location-aware tour-guide. We have evaluated the guide in an ecological context (fully operational application, real users, real context of use (Abowd & Mynatt, 2000)) during the EuroFlora 2006 international exhibition (EuroFlora). In this chapter, we describe the MADE enhancement to support RFID-based applications, present the main concepts of the interaction modalities we have designed in order to support visually impaired users, and discuss results from our field experience.
8
Bellotti, Francesco, Riccardo Berta, Alessandro De Gloria, and Massimiliano Margarone. "Widely Usable User Interfaces on Mobile Devices with RFID." In Human Computer Interaction, 1234–50. IGI Global, 2009. http://dx.doi.org/10.4018/978-1-87828-991-9.ch078.
Full textAbstract:
Diffusion of radio frequency identification (RFID) promises to boost the added value of assistive technologies for mobile users. Visually impaired people may benefit from RFID-based applications that support users in maintaining “spatial orientation” (Mann, 2004) through provision of information on where they are, and a description of what lies in their surroundings. To investigate this issue, we have integrated our development tool for mobile device, (namely: MADE, Bellotti, Berta, De Gloria, & Margarone, 2003), with a complete support for RFID tag detection, and implemented an RFID-enabled location-aware tour-guide. We have evaluated the guide in an . ecological context (fully operational application, real users, real context of use (Abowd & Mynatt, 2000)) during the EuroFlora 2006 international exhibition (EuroFlora). In this chapter, we describe the MADE enhancement to support RFID-based applications, present the main concepts of the interaction modalities we have designed in order to support visually impaired users, and discuss results from our field experience.
9
Aubinet, M., A. Grelle, A. Ibrom, Ü. Rannik, J. Moncrieff, T. Foken, A. S. Kowalski, et al. "Estimates of the Annual Net Carbon and Water Exchange of Forests: The EUROFLUX Methodology." In Advances in Ecological Research, 113–75. Elsevier, 1999. http://dx.doi.org/10.1016/s0065-2504(08)60018-5.
Full text
10
"WHAT IS RIGHT AND WHAT IS WRONG IN THE ECJ’S JUDGMENT ON EUROFOOD IFSC LTD." In Yearbook of Private International Law. Berlin, New York: Sellier de Gruyter, 2009. http://dx.doi.org/10.1515/9783866537194.1.87.
Full textConference papers on the topic "Euroflow"
1
Burzio, Gianfranco, Giacomo Mussino, Roberto Tadei, Guido Perboli, Mauro Dell'Amico, and Leandro Guidotti. "A subjective field test on lane departure warning function in the framework of the euroFOT project." In 2009 2nd Conference on Human System Interactions (HSI). IEEE, 2009. http://dx.doi.org/10.1109/hsi.2009.5091047.
Full text